Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study
Abstract Background The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost using a prospective crossover study. Methods Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were rando...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-04-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12886-017-0453-z |
id |
doaj-037b8519ed8e4223947476084c6d3d6e |
---|---|
record_format |
Article |
spelling |
doaj-037b8519ed8e4223947476084c6d3d6e2020-11-24T21:00:19ZengBMCBMC Ophthalmology1471-24152017-04-011711810.1186/s12886-017-0453-zEfficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover studyWonseok Lee0Sunghoon Lee1HyoungWon Bae2Chan Yun Kim3Gong Je Seong4Department of Ophthalmology, International St. Mary’s Hospital, Catholic Kwandong University College of MedicineInstitute of Vision Research, Department of Ophthalmology, Yonsei University College of MedicineInstitute of Vision Research, Department of Ophthalmology, Yonsei University College of MedicineInstitute of Vision Research, Department of Ophthalmology, Yonsei University College of MedicineInstitute of Vision Research, Department of Ophthalmology, Yonsei University College of MedicineAbstract Background The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost using a prospective crossover study. Methods Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were randomized enrolled. Group 1 (“NPT to PT”) patients used preservative-free 0.0015% tafluprost (NPT) for 6 months and then changed to preservative containing 0.0015% tafluprost(PT) for 6 months. Group 2 (“PT to NPT”) patients used preservative containing 0.0015% tafluprost for 6 months and changed to preservative-free 0.0015% tafluprost for 6 months. At 1, 3, 6, 7, 9, and 12 months, we measured intraocular pressure for efficacy and graded corneal erosion, tear break-up time (TBUT), and subjective discomfort. Results A total of 20 patients and 20 eyes were enrolled. In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38–18.46% decrease). Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT. Conclusion Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly. In addition, changing medication from PT to NPT might improve subjective satisfaction and tear break up time. Trial registration The trial registration number is NCT 03104621 (Apr/1/2017). Retrospectively registered.http://link.springer.com/article/10.1186/s12886-017-0453-zTafluprostPreservativeEfficacyTolerability |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wonseok Lee Sunghoon Lee HyoungWon Bae Chan Yun Kim Gong Je Seong |
spellingShingle |
Wonseok Lee Sunghoon Lee HyoungWon Bae Chan Yun Kim Gong Je Seong Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study BMC Ophthalmology Tafluprost Preservative Efficacy Tolerability |
author_facet |
Wonseok Lee Sunghoon Lee HyoungWon Bae Chan Yun Kim Gong Je Seong |
author_sort |
Wonseok Lee |
title |
Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study |
title_short |
Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study |
title_full |
Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study |
title_fullStr |
Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study |
title_full_unstemmed |
Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study |
title_sort |
efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study |
publisher |
BMC |
series |
BMC Ophthalmology |
issn |
1471-2415 |
publishDate |
2017-04-01 |
description |
Abstract Background The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost using a prospective crossover study. Methods Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were randomized enrolled. Group 1 (“NPT to PT”) patients used preservative-free 0.0015% tafluprost (NPT) for 6 months and then changed to preservative containing 0.0015% tafluprost(PT) for 6 months. Group 2 (“PT to NPT”) patients used preservative containing 0.0015% tafluprost for 6 months and changed to preservative-free 0.0015% tafluprost for 6 months. At 1, 3, 6, 7, 9, and 12 months, we measured intraocular pressure for efficacy and graded corneal erosion, tear break-up time (TBUT), and subjective discomfort. Results A total of 20 patients and 20 eyes were enrolled. In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38–18.46% decrease). Generally, subjective satisfaction was improved after changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not when changing from NPT to PT. Conclusion Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly. In addition, changing medication from PT to NPT might improve subjective satisfaction and tear break up time. Trial registration The trial registration number is NCT 03104621 (Apr/1/2017). Retrospectively registered. |
topic |
Tafluprost Preservative Efficacy Tolerability |
url |
http://link.springer.com/article/10.1186/s12886-017-0453-z |
work_keys_str_mv |
AT wonseoklee efficacyandtolerabilityofpreservativefree00015tafluprostinglaucomapatientsaprospectivecrossoverstudy AT sunghoonlee efficacyandtolerabilityofpreservativefree00015tafluprostinglaucomapatientsaprospectivecrossoverstudy AT hyoungwonbae efficacyandtolerabilityofpreservativefree00015tafluprostinglaucomapatientsaprospectivecrossoverstudy AT chanyunkim efficacyandtolerabilityofpreservativefree00015tafluprostinglaucomapatientsaprospectivecrossoverstudy AT gongjeseong efficacyandtolerabilityofpreservativefree00015tafluprostinglaucomapatientsaprospectivecrossoverstudy |
_version_ |
1716780131962322944 |